The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Shares of US biotech giant Amgen were down almost 6% at $233.98 in pre-market trading today, following the company’s release of positive first-quarter 2022 results, but with a sting in the tail relating to back taxes, after markets closed on Wednesday. 28 April 2022
Outlook Therapeutics recently submitted a Biologics License Application to the US Food and Drug Administration for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wAMD). 28 April 2022
The Breast Cancer Aotearoa Coalition (BCAC) says it is deeply disappointed by a report on cancer medicines released by New Zealand’s Cancer Control Agency, the Te Aho o Te Kahu. 28 April 2022
UK drugmaker GlaxoSmithKline has impressed investors with its first quarter 2022 financial results, with its share price closing 3% higher on Wednesday. 27 April 2022
The European Medicines Agency (EMA) has granted access to the Priority Medicines (PRIME) scheme for BCX9250, a novel, oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and developed by BioCryst Pharmaceuticals for the treatment of fibrodysplasia ossificans progressiva (FOP). 27 April 2022
Pfizer and BioNTech have submitted an application to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a 10-µg booster dose of their COVID-19 jab for children aged five to 11 years of age. 27 April 2022
The UK’s Competition and Markets Authority (CMA) said today that it has worked to ensure that pharmaceutical company Aspen’s commitments to reduce prices for life-saving cancer medicines can be enforced in the UK following its exit from the European Union. 27 April 2022
The stock market provided a telling assessment of Protagonist Therapeutics’ presentation of its top-line results from the Phase II IDEAL study evaluating PN-943 in ulcerative colitis (UC). 27 April 2022
Chinese start-up Xbiome, an AI-based microbiome drug development company, has acquired the clinical-stage M201 program from Californian firm Assembly Biosciences. 27 April 2022
Swiss pharma giant Novartis today announced positive top-line results from an interim analysis of the Phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 expression. 27 April 2022
US traded shares of Swiss biotech Molecular Partners closed down 17.8% at $13.89 on Tuesday after it announced that USA-based Amgen, its collaboration partner for MP0310 (AMG 506), has decided to return global rights on MP0310 following a strategic pipeline review. 27 April 2022
An antibody-drug conjugate (ADC) developed by British drugmaker AstraZeneca and its Japanese partner Daiichi Sankyo has been granted Breakthrough Therapy designation (BTD) in the USA. 27 April 2022
The China National Medical Products Administration (NMPA) has recently granted breakthrough therapy (BTD) designation to China’s Innovent Biologic’s IBI310 in combination with Tyvyt (sintilimab) to treat patients with recurrent or metastatic cervical cancer. 27 April 2022
UK-based Mundipharma and US drug developer Cidara Therapeutics have presented data from the Phase III ReSTORE clinical trial of rezafungin in the treatment of candidemia and/or invasive candidiasis at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 27 April 2022
Japanese drugmaker Eisai today announced an article about long-term health outcomes of its investigational anti-amyloid-beta protofibril antibody lecanemab in people living with early Alzheimer’s disease (AD) using simulation modeling was published in a peer-reviewed journal Neurology and Therapy. 27 April 2022
Data and analytics company GlobalData has found that the UK has a thriving oncology-focused startup and venture capital (VC) scene compared to its European neighbors. 26 April 2022
Boston, USA-based biotech start-up Jnana Therapeutics today announced the appointment of Doug Pagán, as both chief financial and chief operating officer. 26 April 2022
French pharma major Sanofi today announced it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of the company’s ambition to attain world-class standards of manufacturing excellence. 26 April 2022
US biotech Apertura Gene Therapy today announced that it has launched with a Series A financing of up to $67 million from Deerfield Management Company to develop genetic medicines using platform technologies that address key limitations of genetic medicine delivery and expression. 26 April 2022
Swiss pharma major Novartis edged marginally higher in the stock market on Tuesday after announcing that its first quarter sales and profits had done the same. 26 April 2022